Europe Allogeneic Human Chondrocyte Market Size Worth US$ 3,440.5 Million | 10.2% CAGR By 2027

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Allogeneic human chondrocyte is an emerging therapy, which can be used for cartilage repair and other indications. Currently, very few market players are developing these therapies, wherein the studies are in clinical trial phase and are expected to soon receive approval from the regulatory agencies. For instance, Invossa, from Kolon TissueGene, Inc., is expected to be the world’s first cell-and-gene therapy for osteoarthritis. This therapy is going to be a cartilage cells extracted from human cartilage (first fluid of HC) and transformed cells with TGF-β1 (second fluid of TC) by the ratio of 3:1. The product is currently in phase 3 clinical trial phase. This is expected to create lucrative opportunity for players to develop such therapies in the near future.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4088

The Europe allogeneic human chondrocyte market is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2% during the forecast period (2026-2027).

Figure 1. Europe Allogeneic Human Chondrocyte Market Share (%) in Terms of Value, By Country, 2027

Rising incidence of falls and knee cartilage injuries is expected to propel the market growth during the forecast period

Increasing cases of falls and knee cartilage injuries is a major factor that is expected to propel growth of the Europe allogeneic human chondrocyte market over the forecast period. According to the article published in the British Medical Journal (BMJ Journal) February 2020, the incidence of falls in European countries were as follows in 2017: in the Western European region, 13,840 per 100,000 population seek medical treatment for fall related injury, of which 7,594/100,000 are from Greece and 19,796 are from Norway.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4088

Figure 2. Europe Allogeneic Human Chondrocyte Market Share (%), by Application, 2027

Increasing prevalence of musculoskeletal system disorders is expected to propel the market growth over the forecast period

Increasing cases of musculoskeletal system disorders is expected to drive the market growth during the forecast period. According to the State of Musculoskeletal Health, 2019 report by the Versus Arthritis, the prevalence of musculoskeletal conditions in the U.K. in 2017, was as follows:

CountryPrevalence of Musculoskeletal Conditions

England	15,899,000
Scotland	1,525,000
Northern Ireland	487,200
Wales	887,000

Europe Allogeneic Human Chondrocyte Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic is affecting clinical trials, drastically. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they have stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/europe-allogeneic-human-chondrocyte-market-3345

Furthermore, ongoing clinical trials are being conducted by healthcare facilities and researchers using the following safety measures:

• The healthcare providers are obtaining patient consent through phone or video conferences. According to a survey conducted by Medidata Solutions, Inc. on April 23, 2020, 45% of the respondents opted for virtual/telemedicine for consultancy
• Patients receive a phone call for the screening of COVID-19 symptoms before they schedule in-person visits
• The assessment of the studies are being done in single outpatient areas

Europe Allogeneic Human Chondrocyte Market Restraints:

As the research for human allogeneic chondrocyte is ongoing and products are majorly in the development phase, the research cost and procedures are considerably high and tedious, which can affect the development of such products and is expected to hinder growth of the market.

Moreover, the disadvantages of allogeneic transplantation as compared to autologous transplantation is expected to limit the adoption of allogeneic transplantation, thereby hindering the Europe allogeneic human chondrocyte market growth.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/4088

Key Players

Major players operating in the Europe allogeneic human chondrocyte market include Kolon TissueGene, Inc. and ISTO Technologies Inc.

Detailed Segmentation:

• Europe Allogeneic Human Chondrocyte Market, By Application:
  • Osteoarthritis
  • Musculoskeletal System Disorders
  • Others
• Europe Allogeneic Human Chondrocyte Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
• Europe Allogeneic Human Chondrocyte Market, By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837